Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + pembrolizumab + pertuzumab + trastuzumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination regimen is a multi-agent neoadjuvant chemo-immunotherapy consisting of the microtubule-stabilizing taxane paclitaxel, the PD-1 checkpoint inhibitor pembrolizumab, and the dual HER2-targeted monoclonal antibodies trastuzumab and pertuzumab. It is primarily investigated for the treatment of previously untreated, stage II-III, human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The regimen aims to leverage the synergy between HER2-directed therapy and immune checkpoint inhibition to improve pathologic complete response (pCR) rates. Trastuzumab and pertuzumab provide dual HER2 blockade by binding to distinct epitopes of the receptor, while paclitaxel provides cytotoxic activity and pembrolizumab enhances the anti-tumor immune response by blocking the PD-1/PD-L1 inhibitory pathway.
- Other names
- THP-KTHP-pembrolizumab
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on paclitaxel + pembrolizumab + pertuzumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + pembrolizumab + pertuzumab + trastuzumab.